UnknownPhase 4

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

Norway30 participantsStarted 2017-04-18

Plain-language summary

The purpose of this study is to switch from insulin to oral sulfonylurea in patients with apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated. The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).

Who can participate

Age range2 Years – 95 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diabetes and DNA sequence variant of unknown significance (VUS, class 3) or pathogenic (class 4, and 5) in the HNF1A, HNF4A, or HNF1B genes * On insulin treatment * Willing and able to provide informed consent (parents if younger than 16 years of age) Exclusion Criteria: * Known anaphylactic response to sulfonylurea * Diabetes and DNA sequence variant in the HNF1A, HNF4A, or HNF1B genes that are known to be non-pathogenic (class 1-2) * Not willing or able to provide informed consent (parents if younger than 16 years of age)

What they're measuring

Effect of sulfonylurea treatment on insulin requirement measured in units insulin per kg per day

Timeframe: 5 years

Metabolic control of diabetes measured by HbA1c in mmol/mol

Timeframe: 5 years

Trial details

NCT IDNCT04239586

SponsorHaukeland University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04

View on ClinicalTrials.gov More Maturity-Onset Diabetes of the Young, Type 3 trials